226 related articles for article (PubMed ID: 22515611)
41. Personalized tamoxifen: a step closer but miles to go.
Bardia A; Stearns V
Clin Cancer Res; 2010 Sep; 16(17):4308-10. PubMed ID: 20651057
[TBL] [Abstract][Full Text] [Related]
42. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
Opdam FL; Dezentje VO; den Hartigh J; Modak AS; Vree R; Batman E; Smorenburg CH; Nortier JW; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):593-601. PubMed ID: 23228987
[TBL] [Abstract][Full Text] [Related]
43. The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.
Sanchez-Spitman AB; Moes DA; Gelderblom H; Dezentjé VO; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Aug; 18(12):1125-1132. PubMed ID: 28745555
[TBL] [Abstract][Full Text] [Related]
44.
Tamura K; Imamura CK; Takano T; Saji S; Yamanaka T; Yonemori K; Takahashi M; Tsurutani J; Nishimura R; Sato K; Kitani A; Ueno NT; Mushiroda T; Kubo M; Fujiwara Y; Tanigawara Y
J Clin Oncol; 2020 Feb; 38(6):558-566. PubMed ID: 31821071
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
Johnson MD; Zuo H; Lee KH; Trebley JP; Rae JM; Weatherman RV; Desta Z; Flockhart DA; Skaar TC
Breast Cancer Res Treat; 2004 May; 85(2):151-9. PubMed ID: 15111773
[TBL] [Abstract][Full Text] [Related]
46. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
[TBL] [Abstract][Full Text] [Related]
47. CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
Margolin S; Lindh JD; Thorén L; Xie H; Koukel L; Dahl ML; Eliasson E
Pharmacogenomics; 2013 Apr; 14(6):613-22. PubMed ID: 23570465
[TBL] [Abstract][Full Text] [Related]
48. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
Seruga B; Amir E
Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
[TBL] [Abstract][Full Text] [Related]
49. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis.
Jung JA; Lim HS
Pharmacogenomics; 2014 Jan; 15(1):49-60. PubMed ID: 24329190
[TBL] [Abstract][Full Text] [Related]
50. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Irvin WJ; Walko CM; Weck KE; Ibrahim JG; Chiu WK; Dees EC; Moore SG; Olajide OA; Graham ML; Canale ST; Raab RE; Corso SW; Peppercorn JM; Anderson SM; Friedman KJ; Ogburn ET; Desta Z; Flockhart DA; McLeod HL; Evans JP; Carey LA
J Clin Oncol; 2011 Aug; 29(24):3232-9. PubMed ID: 21768473
[TBL] [Abstract][Full Text] [Related]
51. Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Fox P; Balleine RL; Lee C; Gao B; Balakrishnar B; Menzies AM; Yeap SH; Ali SS; Gebski V; Provan P; Coulter S; Liddle C; Hui R; Kefford R; Lynch J; Wong M; Wilcken N; Gurney H
Clin Cancer Res; 2016 Jul; 22(13):3164-71. PubMed ID: 26847054
[TBL] [Abstract][Full Text] [Related]
52. One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity.
Hertz DL; Rae JM
Pharmacogenomics; 2016 Jun; 17(8):823-6. PubMed ID: 27249031
[No Abstract] [Full Text] [Related]
53. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
Thorén L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
Br J Clin Pharmacol; 2021 Mar; 87(3):1243-1252. PubMed ID: 32713032
[TBL] [Abstract][Full Text] [Related]
54. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
[TBL] [Abstract][Full Text] [Related]
55. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
Peppercorn J; A Carey L
Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
[TBL] [Abstract][Full Text] [Related]
56. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
57. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
58. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.
Schroth W; Hamann U; Fasching PA; Dauser S; Winter S; Eichelbaum M; Schwab M; Brauch H
Clin Cancer Res; 2010 Sep; 16(17):4468-77. PubMed ID: 20515869
[TBL] [Abstract][Full Text] [Related]
59. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
[TBL] [Abstract][Full Text] [Related]
60. Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?
Huber-Wechselberger AE; Niedetzky P; Aigner I; Haschke-Becher E
Wien Med Wochenschr; 2012 Jun; 162(11-12):252-61. PubMed ID: 22688624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]